Friday, 30 July 2021
The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient...
Guidance on submission of covid-19 vaccine applications for emergency use authorisation and registration have been published. Click MCAZ COVID-19 VACCINE GUIDANCE-VERSION 11 download the guideline.
In order to improve service delivery to our valued customers, MCAZ collects information on Customer Complaints. To download the 2019 Customer Complaints Trends Analysis Click here
The Medicines Control Authority of Zimbabwe (MCAZ) Covid-19 Health and Safety Guidelines applies to MCAZ staff with the intention of preventing workplace infections, protecting lives, and promoting employee health for...
The draft Blood and Blood Components Regulations are now available Please note that this is a DRAFT that has been uploaded to obtain comments from stakeholders before the regulations are...
This Medical Product Alert warns consumers, healthcare professionals, and health authorities against a growing number of falsified medical products that claim to prevent, detect, treat orcure COVID-19. Medical...
Draft SADC Variations Guidelines are now available Click the following links to download the guidelines and the comments sheet Draft SADC Variations Guidelines Draft SADC Variations Guidelines Comments Sheet
In pursuit of promoting high ethical standards, the Authority has formulated a Code of Ethics for its employees and members of the Authority .The Authority believes that high ethical...
Southern African Development Community (SADC), as a region has harmonized medicines registration guidelines in the common technical document (CTD) format that were approved in January 2015. Nevertheless, the harmonization...
Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme Click here to download the 2018 Drug Information Bulletin
Inside this issue: E-Reporting Tools Safety Notifications for Fluoroquinolones and Quinolones Antibiotics Notification of a potential risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) in patients treated...
